Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03266588 · ClinicalTrials.gov registry record · Phase 2
Open Label Safety Study in Acute Treatment of Migraine
A Phase 2 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
- 3,019
- Enrollment target
NCT03266588 is a Phase 2 study that has completed, run by Pfizer. The registered enrollment target is 3,019 participants.
The verdict
NCT03266588, a Phase 2 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 3,019 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate safety and tolerability of BHV-3000 (rimegepant).
Interventions
- DRUG Rimegepant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,019 participants |
| Start Date | 2017-08-30 |
| Est. Completion | 2019-07-15 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03266588
The ClinicalTrials.gov registry entry for NCT03266588 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 3,019 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Rimegepant is the first listed.
NCT03266588 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03266588 about?
NCT03266588 is a clinical study titled "Open Label Safety Study in Acute Treatment of Migraine". The purpose of this study is to evaluate safety and tolerability of BHV-3000 (rimegepant).
What is the current status of trial NCT03266588?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 3,019 participants. The study started on 2017-08-30. Estimated completion is 2019-07-15.
What interventions are being tested in trial NCT03266588?
The interventions under investigation include: Rimegepant (DRUG).
Who is sponsoring clinical trial NCT03266588?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.